Top 10 Alzheimer’s Disease Stories of 2019

Top 10 Alzheimer’s Disease Stories of 2019
Throughout 2019, Alzheimer's News Today delivered daily coverage of emerging research, key findings, treatment developments, and clinical trials related to Alzheimer's disease. We look forward to bringing the same quality of coverage to those living with Alzheimer's in the coming year. Here are the 10 most-read stories of 2019, with brief summaries of what made each one relevant to the Alzheimer's community. No. 10 – “Phase 2 Trial of Tau Antibody RO7105705 Recruiting Patients with Moderate Alzheimer’s” Genentech began enrolling patients into a Phase 2 trial (NCT03828747) to measure how an experimental compound called RO7105705 affects cognitive function and functional abilities in Alzheimer's patients over a 49-week period. The compound is a humanized monoclonal antibody designed to prevent toxic forms of tau protein from spreading between cells within the brain. The spread of tau protein is known to hasten the onset and progression of cognitive decline in Alzheimer’s disease. Given Tau's central role in Alzheimer's, several other anti-Tau drug trials are underway, including another Phase 2 trial run by Genentech (NCT03289143), a Phase 1b/2a trial of an anti-Tau vaccine, and early-stage trials of Tau aggregation blockers. No. 9 – “Diet Directly Affects Gut Bacteria and May Contribute to Alzheimer’s Progression, Pilot Study Suggests” A modified Mediterranean-ketogenic diet can regulate bacteria in the gut that may contribute to the development and progression of cognitive impairment and Alzheimer’s disease, according to a recent pilot study (NCT02984540). Among 17 study participants, the Mediterranean diet led to unique microbial patterns in 11 patients with mild cognitive impairment, which corresponded with reduced levels of tau pro
Subscribe or to access all post and page content.